Market Snapshot: Anti-TNFs Grow Despite Tough Market
Executive Summary
At least one class of therapies - anti-tumor necrosis factors - is booming, even in the midst of one of the worst years financially for the pharmaceutical industry
You may also be interested in...
Korea’s Celltrion Looks To Help Patients Pay For Remicade Biosimilar
Although the price of Celltrion’s biosimilar is lower than J&J’s Remicade, most patients will not be covered under Korea’s National Health Insurance.
Korea’s Celltrion Looks To Help Patients Pay For Remicade Biosimilar
Although the price of Celltrion’s biosimilar is lower than J&J’s Remicade, most patients will not be covered under Korea’s National Health Insurance.
Amgen Shifts Its Focus From Products To Pipeline, But Stays In Comfort Zone
Amgen Inc. is sticking to what it knows as it finally moves some of its mid-stage pipeline into later stages. Two of its most promising pipeline candidates, AMG 827 and AMG 785, are intended to be follow-on products to two of Amgen’s biggest franchises: Enbrel (etanercept) and Prolia/Xgeva (denosumab).